<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01813539</url>
  </required_header>
  <id_info>
    <org_study_id>CR108755</org_study_id>
    <secondary_id>ARGX-110-1201</secondary_id>
    <secondary_id>2012-005046-38</secondary_id>
    <nct_id>NCT01813539</nct_id>
  </id_info>
  <brief_title>A Study of ARGX-110 in Participants With Advanced Malignancies</brief_title>
  <official_title>A Phase I/II Study of ARGX-110 in Patients With Advanced Malignancies Expressing CD70.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>argenx BVBA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the optimal dose of ARGX-110 in participants with
      advanced malignancies and to assess efficacy of ARGX-110 (exploratory efficacy cohort 5
      only).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I study conducted in participants whose tumors express the target of interest.
      Pharmacokinetics (PK), pharmacodynamics (PD), biomarkers will be determined to support dose
      selection.

      Phase II study conducted in Cutaneous T-cell lymphoma (CTCL) participants who are CD70
      positive. PK, PD, biomarkers and immunohistochemistry (IHC) will be determined to assess
      efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 27, 2013</start_date>
  <completion_date type="Actual">July 10, 2020</completion_date>
  <primary_completion_date type="Actual">July 10, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Dose Limiting Toxicity (DLT)</measure>
    <time_frame>21 days</time_frame>
    <description>DLT is defined as drug-related grade 3 or 4 clinical adverse event (AE) occurring during the 21 days (3 weeks) following the first dose of ARGX-110.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of ARGX-110</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Plasma concentration of ARGX-110 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers (CD70 qPCR and sCD27) of ARGX-110 biological activity</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Biomarkers (CD70 quantitative polymerase chain reaction [CD70 qPCR] and soluble CD27 [sCD27]) will be measured in serum and on tumor samples to correlate systemic drug effects with AE and Tumor response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants who Achieve a Tumor Response</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Tumor response will be assessed according to RECIST.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Dose Escalation: Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ARGX-110 as an intravenous infusion (IV) at dose level 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation: Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ARGX-110 as an IV infusion at dose level 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation: Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ARGX-110 as an IV infusion at dose level 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation: Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ARGX-110 as an IV infusion at dose level 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation: Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ARGX-110 as an IV infusion at intermediate dose level at the conclusion of Cohort 4 prior to opening the safety expansion cohorts to participants enrolment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Safety Expansion: Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with solid tumors will receive ARGX-110 as an IV infusion at a dose based on the safety, PD, and PK profiles of ARGX-110 as per the dose escalation part of the trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Safety Expansion: Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with hematological malignancies (all etiologies) will receive ARGX-110 as an IV infusion at a dose based on the safety, PD, and PK profiles of ARGX-110 as per the dose escalation part of the trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Safety Expansion: Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with cutaneous T-cell lymphoma (CTCL) will receive ARGX-110 as an IV infusion at dose level 2 followed by a maintenance therapy at dose level 2 or 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Safety Expansion: Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with peripheral T-cell lymphoma (PTCL) will receive ARGX-110 as an IV infusion at dose level 2 followed by a maintenance therapy at dose level 2 or 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exploratory Efficacy: Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with relapsed/refractory CTCL will receive ARGX-110 as an IV infusion followed by a maintenance therapy at dose level 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARGX-110</intervention_name>
    <description>ARGX-110 will be administered as an IV infusion.</description>
    <arm_group_label>Dose Escalation: Cohort 1</arm_group_label>
    <arm_group_label>Dose Escalation: Cohort 2</arm_group_label>
    <arm_group_label>Dose Escalation: Cohort 3</arm_group_label>
    <arm_group_label>Dose Escalation: Cohort 4</arm_group_label>
    <arm_group_label>Dose Escalation: Cohort 5</arm_group_label>
    <arm_group_label>Exploratory Efficacy: Cohort 5</arm_group_label>
    <arm_group_label>Safety Expansion: Cohort 1</arm_group_label>
    <arm_group_label>Safety Expansion: Cohort 2</arm_group_label>
    <arm_group_label>Safety Expansion: Cohort 3</arm_group_label>
    <arm_group_label>Safety Expansion: Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological diagnosis of malignancy refractory to, or relapsing after standard
             therapy

          -  Solid tumors or T-cell malignancies positive for the CD70 antigen by
             Immunohistochemistry/Fluorescence-activated cell sorting (IHC/FACS) within 56 days
             prior to administering the first dose of ARGX-110. IHC criterion: greater than &gt; 10
             percent (%) of CD70 positive tumor cells

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, or 2

          -  Serum albumin greater than or equal to (&gt;=) 20 gram per liter (g/L) (solid tumor only)

          -  Ability to comply with protocol-specified procedures/evaluations and scheduled visits.
             In particular, the ability of the patient to undergo a tumor biopsy (optional for
             safety expansion cohort 4)

        Exclusion Criteria:

          -  History or clinical evidence of neoplastic central nervous system (CNS) involvement

          -  History of another primary malignancy that has not been in remission for at least 1
             year

          -  Systemic glucocorticoid administration at doses greater than physiological replacement
             (prednisolone 20 milligram [mg] equivalent) within 28 days of ARGX-110 first dose
             administration (for T-cell malignancies higher systemic dose can be allowed following
             discussion with Sponsor)

          -  Major surgery within 28 days of ARGX-110 first dose administration

          -  Unresolved grade 3 or 4 toxicity from prior therapy, including experimental therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 7, 2013</study_first_submitted>
  <study_first_submitted_qc>March 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2013</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malignancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

